- Janice Hopkins Tanne
- 1New York
The US Food and Drug Administration does a poor job of monitoring drug companies’ promotion of unapproved or “off-label” uses of their drugs, says a report by the US Government Accountability Office, the investigative arm of Congress.
Charles Grassley, an Iowa senator who is the senior Republican member of the Senate Committee on Finance, asked the accountability office to review the FDA’s effectiveness in monitoring drug companies’ efforts to promote off-label uses. He said he was concerned about the possible effects of such promotion on doctors’ prescribing practices and on patients’ safety.
Although doctors may prescribe drugs off label for indications that have not been approved by the FDA, drug companies are forbidden from promoting such unapproved uses.
The accountability office’s report said the FDA’s …
Sign in
Personal subscribers, sign in here:
Article access
Article access for 1 day
Purchase this article for £20 $30 €32*
The PDF version can be downloaded as your personal record
CiteULike
Connotea
Del.icio.us
Digg
Facebook
Reddit
Technorati
Twitter
Stumbleupon
Rapid responses
Latest Responses
Ethical considerations
Published 14 February 2012
Re: Diagnosis and management of Raynaud’s phenomenon
Published 14 February 2012
Re: Raised inflammatory markers
Published 14 February 2012
Re: Physical activity for cancer survivors: meta-analysis of randomised controlled trials
Published 14 February 2012
Smokefree cars in Wales: Laws are better
Published 14 February 2012
Most responses
Does anyone understand the government’s plan for the NHS? (17 responses)
Published 17 Jan 2012
Bad medicine: medical nutrition (15 responses)
Published 18 Jan 2012
Shared decision making: really putting patients at the centre of healthcare (8 responses)
Published 27 Jan 2012
Why legislation is necessary for my health reforms (8 responses)
Published 1 Feb 2012
How much of a social media profile can doctors have? (7 responses)
Published 23 Jan 2012